FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES

The response rate to therapy for rheumatoid arthritis (RA) rarely exceeds 60%. Mental disorders (MDs) of the anxiety-depressive spectrum (ADS) and cognitive impairment (CI) substantially affect the evaluation of the efficiency of RA therapy. Adequate psychopharmacotherapy is one of the possible approaches to optimizing the treatment of RA. The factors influencing the efficiency of RA therapy with standard disease-modifying antirheumatic drugs (DMARDs) and biological agents (BAs) in combination with adequate psychopharmacotherapy have not been previously identified. Objective: to determine the predictors of response to therapy in patients with RA receiving DMARDs and BAs with or without adequate psychopharmacotherapy for ADS disorders. Subjects and methods. The investigation included 128 patients (13% men and 87% women) with a reliable diagnosis of RA. At baseline, 75.1% of patients received DMARDs; 7.8% – BAs. ADS disorders were detected in 123 (96.1%) patients. Psychopharmacotherapy was offered to all the patients with MDs; 52 patients agreed to treatment and 71 refused. The following therapeutic groups were identified according to the performed therapy: 1) DMARDs (n = 39); 2) DMARDs + psychopharmacotherapy (n = 43); 3) DMARDs + BAs (n = 32); 4) DMARDs + BAs + psychopharmacotherapy (n = 9). The changes of MDs symptoms and the outcomes of RA were assessed in 83 (67.5%) patients at five-year follow-up. The efficiency of RA therapy was evaluated with DAS28 (EULAR criteria). Predictors of response to therapy were determined using linear regression modeling. Results and discussion. At 5 years, 22 (26.5%) and 37 (44.6%) patients were recorded to show good and moderate responses to therapy, respectively; 24 (28.9%) patients were non-respondents. The linear regression model included 14 factors (p<0.001). The high values of DAS28 (β=0.258) at the inclusion; belonging to therapeutic groups 2 (β=0.267), 3 (β=0.235), and 4 (β=0.210), the absence of diabetes mellitus (β=-0.230), and experience in using glucocorticoids (β=-0.230) were associated with a high likelihood of response to therapy; high body mass index (β=-0.200) and long RA duration (β=-0,181), a high level of rheumatoid factor (β=-0.176), a history of myocardial infarction (β=-0.153), schizotypic disorder (β=-0.132), and extra-articular manifestations of RA (β=-0.106), and older age (β=-0.102) were related to a low probability of response. The area under the ROC curve for the model was 0.99 (p><0.001). Conclusion. BA therapy and psychopharmacotherapy, along with younger age, shorter duration and high activity of RA, a low level of rheumatoid factor, lower body mass index, the absence of diabetes mellitus, myocardial infarction, and extra-articular manifestations of RA in the history, schizotypic disorder, and experience in using glucocorticoids are associated with a greater likelihood of a good and moderate treatment response. Keywords: rheumatoid arthritis; mental disorders; disease-modifying antirheumatic drugs; biological agents; efficiency of therapy; predictors; psychopharmacotherapy; therapy adherence><0.001). The high values of DAS28 (β=0.258) at the inclusion; belonging to therapeutic groups 2 (β=0.267), 3 (β=0.235), and 4 (β=0.210), the absence of diabetes mellitus (β=-0.230), and experience in using glucocorticoids (β=-0.230) were associated with a high likelihood of response to therapy; high body mass index (β=-0.200) and long RA duration (β=-0,181), a high level of rheumatoid factor (β=-0.176), a history of myocardial infarction (β=-0.153), schizotypic disorder (β=-0.132), and extra-articular manifestations of RA (β=-0.106), and older age (β=-0.102) were related to a low probability of response. The area under the ROC curve for the model was 0.99 (p<0.001). Conclusion. BA therapy and psychopharmacotherapy, along with younger age, shorter duration and high activity of RA, a low level of rheumatoid factor, lower body mass index, the absence of diabetes mellitus, myocardial infarction, and extra-articular manifestations of RA in the history, schizotypic disorder, and experience in using glucocorticoids are associated with a greater likelihood of a good and moderate treatment response. Keywords: rheumatoid arthritis; mental disorders; disease-modifying antirheumatic drugs; biological agents; efficiency of therapy; predictors; psychopharmacotherapy; therapy adherence><0.001). Conclusion. BA therapy and psychopharmacotherapy, along with younger age, shorter duration and high activity of RA, a low level of rheumatoid factor, lower body mass index, the absence of diabetes mellitus, myocardial infarction, and extra-articular manifestations of RA in the history, schizotypic disorder, and experience in using glucocorticoids are associated with a greater likelihood of a good and moderate treatment response.

1. Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016;353:i1777. doi: 10.1136/bmj.i1777

2. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis. Ann Intern Med. 2008;148(2):124. doi: 10.7326/0003-4819-148-2-200801150-00192

3. Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1113-36. doi: 10.1136/annrheumdis-2016-210713

4. Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014;6(6):CD000957. doi: 10.1002/14651858.CD000957.pub2

5. Wijbrandts CA, Tak PP. Prediction of Response to Targeted Treatment in Rheumatoid Arthritis. Mayo Clin Proc. 2017;92(7):1129-43. doi: 10.1016/j.mayocp.2017.05.009

6. Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2015;55(3):kev374.

7. doi: 10.1093/rheumatology/kev374

8. Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol. 2017;13(8):503-10. doi: 10.1038/nrrheum.2017.81

9. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38. doi: 10.1016/S0140-6736(16)30173-8

10. Lisitsyna TA, Veltishchev DYu. Mental disorders in patients with rheumatic diseases: Diagnosis and treatment. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):512-21 (In Russ.)]. doi: 10.14412/1995-4484-2015-512-521

11. Matcham F, Norton S, Scott DL, et al. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology (Oxford). 2015;55(2):269-78. doi: 10.1093/rheumatology/kev306

12. Lu M-C, Guo H-R, Lin M-C, et al. Bidirectional associations between rheumatoid arthritis and depression: a nationwide longitudinal study. Sci Rep. 2016;6(February):20647. doi: 10.1038/srep20647

13. Benka J, Nagyova I, Rosenberger J, et al. Social participation in early and established rheumatoid arthritis patients. Disabil Rehabil. 2016;38(12):1172-9. doi: 10.3109/09638288.2015.1076071

14. Feldthusen C, Grimby-Ekman A, Forsblad-D’Elia H, et al. Explanatory factors and predictors of fatigue in persons with rheumatoid arthritis: A longitudinal study. J Rehabil Med. 2016;48(5):469-76. doi: 10.2340/16501977-2090

15. Curtis JR, Bykerk VP, Aassi M, et al. Adherence and persistence with methotrexate in rheumatoid arthritis: A systematic review. J Rheumatol. 2016;43(11):1997-2009. doi: 10.3899/jrheum.151212

16. Markenson JA, Koenig AS, Feng JY, et al. Comparison of Physician and Patient Global Assessments Over Time in Patients With Rheumatoid Arthritis. J Clin Rheumatol. 2013;19(6):317-23. doi: 10.1097/RHU.0b013e3182a2164f

17. Euesden J, Matcham F, Hotopf M, et al. The Relationship Between Mental Health, Disease Severity, and Genetic Risk for Depression in Early Rheumatoid Arthritis. Psychosom Med. 2017;79(6):638-45. doi: 10.1097/PSY.0000000000000462

18. Rathbun AM, Harrold LR, Reed GW. Temporal effect of depressive symptoms on the longitudinal evolution of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2015;67(6):765-75. doi: 10.1002/acr.22515

19. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. doi: 10.1002/art.27584

20. Nasonov EL. Revmatologiya. Rossiyskie klinicheskie rekomendatsii [Rheumatology. Russian Clinical Recommendations]. Moscow: GEOTAR-Media; 2017 (In Russ.)

21. Amirdzhanova VN, Koylubaeva GN, Goryachev DV, et al. The validation of the Russian version of the Health Assessment Questionnaire (HAQ). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2004;42(2):59-64 (In Russ.)

22. Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745-57, vii–viii. doi: 10.1016/j.rdc.2009.10.001

23. Van Gestel AM, Prevoo ML, van’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40. doi: 10.1002/art.1780390105

24. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x

25. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. doi: 10.1111/j.2044-8341.1959.tb00467.x

26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9. doi: 10.1192/bjp.134.4.382

27. Luriya AR. Vysshie korkovye funktsii cheloveka i ikh narusheniya pri lokal'nykh porazheniyakh mozga [Higher cortical functions of a person and their violation in cases of local brain damage]. 2nd ed. Moscow: MSU Publishing House; 1962 (In Russ.)

28. Khersonskiiy BG. Metod piktogramm v psikhodiagnostike psikhicheskikh zabolevaniiy [The method of pictograms in the psychodiagnosis of mental illness]. Kiev: Zdorov’ia, 1988 (In Russ.)

29. World Health Organization. The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research. 1993: xiii+248p. doi: 10.1002/1520-6505(2000)9:5<201::AID-EVAN2>3.3.CO;2-P

30. Zeygarnik BV. Patologiya myshleniya [Pathology of Thinking]. 2nd ed. Moscow: MSU Publishing House; 1962 (In Russ.)

31. Prostye analogii. Al'manakh psikhologicheskikh testov [Simple analogies. Almanac of psychological tests]. 3rd ed. Moscow: «KSP»; 1995 (In Russ.)

32. Rubinshteyn SYa, Butenko G, editor. Eksperimental'nye metodiki patopsikhologii i opyt primeneniya ikh v klinike [Experimental methods of pathopsychology and experience of their application in the clinic]. Moscow: Publishing house of the Institute of Psychotherapy; 2010 (In Russ.)

33. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders?: DSM-IV-TR. American Psychiatric Association; 2000.

34. Gerasimov AN. Meditsinskaya statistika: uchebnoe posobie [Medical statistics: textbook]. Moscow: Meditsinskoe informatsionnoe agentstvo; 2007 (In Russ.)

35. Abramkin AA. Impact of comorbid mental disorders on the efficiency of therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):339-45 (In Russ.)]. doi: 10.14412/1995-4484-2016-339-34

36. Lee K-E, Choi S-E, Xu H, et al. HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis. Rheumatol Int. 2017;37(12):2027-34. doi: 10.1007/s00296-017-3833-z

37. Katchamart W, Johnson S, Lin H-JL, et al. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken). 2010;62(8):1128-43. doi: 10.1002/acr.20188

38. Yu MB, Firek A, Langridge WHR. Predicting methotrexate resistance in rheumatoid arthritis patients. Inflammopharmacology. March 12, 2018:1-10. doi: 10.1007/s10787-018-0459-z

39. Romao VC, Vital EM, Fonseca JE, et al. Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? Arthritis Res Ther. 2017;19(1):239. doi: 10.1186/s13075-017-1445-3

40. Hamann P, Holland R, Hyrich K, et al. Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. Arthritis Care Res (Hoboken). 2017;69(6):783-93. doi: 10.1002/acr.23016

41. Kleinert S, Tony HP, Krause A, et al. Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: Data from a German noninterventional observational study. Rheumatol Int. 2012;32(9):2759-67. doi: 10.1007/s00296-011-2033-5

42. Mikuls TR, O’Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004;50(12):3776-82. doi: 10.1002/art.20659

43. Pers Y-M, Fortunet C, Constant E, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology (Oxford). 2014;53(1):76-84. doi: 10.1093/rheumatology/ket301

44. Albrecht K, Luque Ramos A, Hoffmann F, et al. High prevalence of diabetes in patients with rheumatoid arthritis: results from a questionnaire survey linked to claims data. Rheumatology (Oxford). 2017;57(2):329-36. doi: 10.1007/s00393-017-0294-4

45. Asai S, Fujibayashi T, Oguchi T, et al. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study. Mod Rheumatol. March 4, 2017:1-6. doi: 10.1080/14397595.2017.1332558

46. Akter N, Qureshi NK, Hoque MA, et al. Extra-Articular Manifestations of Rheumatoid Arthritis & its relation with Treatment Outcome: a tertiary care hospital experience. KYAMC J. 2015;6(1):570-3. doi: 10.3329/kyamcj.v6i1.32784

47. Soliman MM, Hyrich KL, Lunt M, et al. Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register. J Rheumatol. 2012;39(2):240-6. doi: 10.3899/jrheum.110610

48. McWilliams DF, Ferguson E, Young A, et al. Discordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data. Arthritis Res Ther. 2016;18(1):295. doi: 10.1186/s13075-016-1186-8

49. Scheiman-Elazary A, Duan L, Shourt C, et al. The rate of adherence to antiarthritis medications and associated factors among patients with rheumatoid arthritis: A systematic literature review and metaanalysis. J Rheumatol. 2016;43(3):512-23. doi: 10.3899/jrheum.141371

50. Joshi K, Lin J, Lingohr-Smith M, et al. Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States. J Clin Psychopharmacol. 2016;36(5):429-35.

51. doi: 10.1097/JCP.0000000000000549

52. Gray R, Bressington D, Ivanecka A, et al. Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis. BMC Psychiatry. 2016;16:90. doi: 10.1186/s12888-016-0801-1

53. Jain A, Bhadauria D. Evaluation of efficacy of fluoxetine in the management of major depression and arthritis in patients of Rheumatoid Arthritis. Ind J Rheumatol. 2013;8(4):165-9. doi: 10.1016/j.injr.2013.08.001

54. Kekow J, Moots R, Khandker R, et al. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford). 2011;50(2):401-9. doi: 10.1093/rheumatology/keq327

55. Karpouzas GA, Draper T, Moran R, et al. Trends in functional disability and determinants of clinically meaningful change over time in Hispanics with Rheumatoid arthritis in the United States. Arthritis Care Res. 2016;69(2):294-8. doi: 10.1002/acr.22924

56. Fiest KM, Hitchon CA, Bernstein CN, et al. Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons With Rheumatoid Arthritis. J Clin Rheumatol. 2017;00(00):1. doi: 10.1097/RHU.0000000000000489